Cellnovo Group (“Cellnovo” or the “Company” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, today announces its sales for the first half and second quarter ended June 30, 2017. Sophie Baratte, Chief Executive Officer of Cellnovo, commented: “Cellnovo is now perfectly positioned to capitalise on the potential of its unique diabetes management system with production capacity on the cusp of ramp-up, a strong network of international distributors in place and a healthy cash position to support its commercial ambitions. The decrease in sales reported today is in line with the Company’s strategy to limit sales of systems for new patients until the full ramp-up of insulin cartridge production takes place. This is expected to begin in August, with delivery of cartridges to Cellnovo expected in September.